Metabiomed KRX:059210KOSDAQ
메타바이오메드 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days1
Articles tracked0since Sep 11
In Q2 2026, Metabiomed reported revenue of ₩27.0bn, up 6.0% year on year, and operating profit of ₩6.3bn. Metabiomed (메타바이오메드) appeared in 0 Korean news articles and 1 DART filing over the past seven days.
Filing signals Op. margin 20%+ Screener
Metabiomed quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩27.0bn | +6.0% | ₩6.3bn | ₩6.3bn |
| Q1 2026 | ₩24.4bn | -11.8% | ₩4.9bn | ₩4.4bn |
| Q4 2025 derived | ₩26.2bn | +13.8% | ₩2.9bn | ₩1.6bn |
| Q3 2025 | ₩23.5bn | +1.7% | ₩5.1bn | ₩4.5bn |
| Q2 2025 | ₩25.5bn | +0.6% | ₩7.8bn | −₩884m |
| Q1 2025 | ₩27.7bn | +23.1% | ₩5.6bn | ₩5.6bn |
| Q4 2024 derived | ₩23.1bn | +8.1% | ₩4.8bn | ₩9.0bn |
| Q3 2024 | ₩23.1bn | +10.6% | ₩3.8bn | ₩3.7bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
Metabiomed top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest Metabiomed news Korean headlines
No articles yet.